Workflow
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
BEAMBeam Therapeutics(BEAM) ZACKS·2024-08-07 15:52

Beam Therapeutics Inc. (BEAM) incurred a loss of 1.11pershareinthesecondquarterof2024,narrowerthantheZacksConsensusEstimateofalossof1.11 per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 1.13. The company had recorded a loss of 1.08pershareintheyear−agoquarter.Totalrevenues,comprisinglicenseandcollaborationrevenues,cameinat1.08 per share in the year-ago quarter. Total revenues, comprising license and collaboration revenues, came in at 11.7 million in the second quarter compared with 20.1millionreportedintheyear−agoperiod.ThetoplinemissedtheZacksConsensusEstimateof20.1 million reported in the year-ago period. The top line missed the Zacks Consensus Estimate of 14 million. Quarter in Detail Research and developmen ...